Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Amortization - Deferred ChargesCost of RevenueEBIATGross ProfitMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Fennec Pharmaceuticals (FENC) Cost of Revenue (2023 - 2025)

Fennec Pharmaceuticals filings provide 3 years of Cost of Revenue readings, the most recent being $6.1 million for Q4 2025.

  • On a quarterly basis, Cost of Revenue rose 54.82% to $6.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $12.7 million, a 20.27% increase, with the full-year FY2025 number at $18.6 million, up 1.03% from a year prior.
  • Cost of Revenue hit $6.1 million in Q4 2025 for Fennec Pharmaceuticals, up from $5.2 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $6.1 million in Q4 2025 to a low of $95000.0 in Q1 2023.
  • Median Cost of Revenue over the past 3 years was $2.9 million (2023), compared with a mean of $2.7 million.
  • Biggest five-year swings in Cost of Revenue: skyrocketed 478.95% in 2024 and later tumbled 79.3% in 2025.
  • Fennec Pharmaceuticals' Cost of Revenue stood at $3.9 million in 2023, then increased by 1.96% to $3.9 million in 2024, then skyrocketed by 54.82% to $6.1 million in 2025.
  • The last three reported values for Cost of Revenue were $6.1 million (Q4 2025), $5.2 million (Q3 2025), and $967000.0 (Q2 2025) per Business Quant data.